title: Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells.
abstract: Constitutively-activated JAK/Stat3 or Src/Stat3 signaling plays a crucial role in tumor cell survival, proliferation, angiogenesis and immune suppression. Activated JAK/Stat3 or Src/Stat3 has been validated as a promising molecular target for cancer therapy. However, prolonged inhibition of Src family kinases (SFKs) leads to reactivation of signal transducer and activator of transcript 3 (Stat3) and tumor cell survival through altered JAK/Stat3 interaction. This compensatory feedback suggests that dual inhibition of Janus kinases (JAKs) and SFKs might be a promising strategy for targeting downstream Stat3 signaling in the clinic. In this study, we identify that the natural product derivative E738 is a novel dual inhibitor of JAKs and SFKs. The IC(50) values of E738 against recombinant JAKs and SFKs in vitro are in the ranges of 0.7-74.1 nM and 10.7-263.9 nM, respectively. We observed that phosphorylation of both Jak2 and Src was substantially inhibited in the submicromolar range by E738 in cultured human pancreatic tumor cells, followed by blockade of downstream Stat3 activation. E738 down-regulated expression of the Stat3 target proteins Mcl-1 and survivin, associated with induction of apoptosis. Computational models and molecular dynamics simulations of E738/Tyk2 or E738/Src in silico suggest that E738 inhibits both tyrosine kinase 2 (Tyk2) and Src as an ATP-competitive ligand. Moreover, the planar E738 molecule demonstrates a strong binding affinity in the compact ATP-binding site of Tyk2. In sum, E738 is the first dual inhibitor of JAKs and SFKs, followed by inhibition of Stat3 signaling. Thus, according to in vitro experiments, E738 is a promising new therapeutic agent for human pancreatic cancer treatment by blocking both oncogenic pathways simultaneously.
authors.affiliation: Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. snam@coh.org
authors.forename: Sangkil
authors.initials: S
authors.lastname: Nam
authors.forename: Wei
authors.initials: W
authors.lastname: Wen
authors.forename: Anne
authors.initials: A
authors.lastname: Schroeder
authors.forename: Andreas
authors.initials: A
authors.lastname: Herrmann
authors.forename: Hua
authors.initials: H
authors.lastname: Yu
authors.forename: Xinlai
authors.initials: X
authors.lastname: Cheng
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Merz
authors.forename: Gerhard
authors.initials: G
authors.lastname: Eisenbrand
authors.forename: Hongzhi
authors.initials: H
authors.lastname: Li
authors.forename: Yate-Ching
authors.initials: YC
authors.lastname: Yuan
authors.forename: Richard
authors.initials: R
authors.lastname: Jove
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000494:pharmacology; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008958:Models, Molecular; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D050796:STAT3 Transcription Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D019061:src-Family Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D050796:STAT3 Transcription Factor; D053612:Janus Kinases; D019061:src-Family Kinases; C027185:indirubin